Possible role of procathepsin D in human cancer
Language English Country United States Media print
Document type Journal Article, Review
PubMed
15954536
DOI
10.1007/bf02931296
Knihovny.cz E-resources
- MeSH
- Cathepsin D immunology metabolism MeSH
- Humans MeSH
- Biomarkers, Tumor MeSH
- Neoplasms enzymology prevention & control MeSH
- Enzyme Precursors immunology metabolism MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Names of Substances
- Cathepsin D MeSH
- Biomarkers, Tumor MeSH
- Enzyme Precursors MeSH
- procathepsin D MeSH Browser
For the past ten years, our research has been focused on elucidating the mechanism by which procathepsin D (pCD) impacts cancer development. Various studies have shown that pCD is overexpressed and secreted by numerous cancer cell lines. After secretion, it exhibits "growth hormone-like" activity on cancerous cells but the exact mechanism of this mitogenic activity is not yet understood. The activation peptide of pCD (APpCD) (which is cleaved off upon activation of the zymogen) is responsible for the mitogenic function of pCD. Various in vitro and in vivo studies support our theory that the APpCD interacts with both parent and neighborhood cancer cells and thus functions as an autocrine mitogen. We propose a model of pCD mitogenic function and also some possible approaches for treatment and prevention of certain types of cancer.
See more in PubMed
Breast Cancer Res Treat. 1995 Aug;35(2):211-20 PubMed
Biochem Mol Biol Int. 1993 Aug;30(5):921-8 PubMed
Bull Acad Natl Med. 1999;183(5):955-68; discussion 968-71 PubMed
Cell. 1980 Jun;20(2):353-62 PubMed
Oncogene. 2001 Oct 18;20(47):6920-9 PubMed
Eur J Cancer. 1992;28A(11):1780-3 PubMed
J Invest Dermatol. 1995 Mar;104(3):340-4 PubMed
Clin Exp Metastasis. 2004;21(2):91-106 PubMed
Cancer. 1997 Jun 1;79(11):2132-6 PubMed
Cancer Lett. 1992 Dec 24;67(2-3):133-8 PubMed
Oncol Rep. 1998 Nov-Dec;5(6):1519-24 PubMed
Mod Pathol. 1994 May;7(4):469-74 PubMed
Cancer. 1993 Sep 15;72(6):1991-6 PubMed
Int J Cancer. 1994 Jun 15;57(6):875-82 PubMed
FEBS Lett. 1993 Mar 15;319(1-2):54-8 PubMed
Epidemiology. 1994 May;5(3):324-31 PubMed
Cancer. 1993 Mar 15;71(6):2006-12 PubMed
Cancer Res. 1994 Jan 1;54(1):48-54 PubMed
Anticancer Res. 1992 Jan-Feb;12(1):235-40 PubMed
Biol Reprod. 1980 Oct;23(3):663-8 PubMed
Acta Oncol. 1992;31(2):125-30 PubMed
EMBO J. 1993 Apr;12(4):1293-302 PubMed
Cancer Res. 1992 Oct 1;52(19):5198-203 PubMed
Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):203-7 PubMed
Int J Cancer. 1997 Nov 4;73(3):403-9 PubMed
Lancet. 1989 Nov 11;2(8672):1115-8 PubMed
Cancer Immunol Immunother. 1998 Mar;46(1):48-54 PubMed
Gynecol Oncol. 1999 Aug;74(2):181-7 PubMed
Biochem J. 1994 Nov 1;303 ( Pt 3):775-80 PubMed
Oncogene. 2002 Aug 1;21(33):5127-34 PubMed
Prostate. 1994 Jun;24(6):320-5 PubMed
Cancer Gene Ther. 2002 Oct;9(10):854-63 PubMed
Cancer Res. 1993 Feb 15;53(4):873-7 PubMed
Biol Chem Hoppe Seyler. 1995 Jun;376(6):357-63 PubMed
Eur J Cancer. 2001 Jan;37(2):155-8 PubMed
Comp Biochem Physiol B Biochem Mol Biol. 2002 Sep;133(1):113-8 PubMed
J Clin Pathol. 1986 Dec;39(12):1323-30 PubMed
J Cell Biochem. 1987 Sep;35(1):17-29 PubMed
FASEB J. 1997 Aug;11(10):785-92 PubMed
J Cell Biochem. 1987 Jan;33(1):53-63 PubMed
Cancer Lett. 1998 Jul 3;129(1):55-9 PubMed
Prostate. 2000 Jun 15;44(1):1-7 PubMed
Breast Cancer Res Treat. 1999 Oct;57(3):261-9 PubMed
Oncogene. 1990 Dec;5(12):1809-14 PubMed
Cathepsin D--many functions of one aspartic protease
